These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
279 related items for PubMed ID: 22695899
1. The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis. Jardine MJ, Kang A, Zoungas S, Navaneethan SD, Ninomiya T, Nigwekar SU, Gallagher MP, Cass A, Strippoli G, Perkovic V. BMJ; 2012 Jun 13; 344():e3533. PubMed ID: 22695899 [Abstract] [Full Text] [Related]
5. Homocysteine-lowering therapy with folic acid is effective in cardiovascular disease prevention in patients with kidney disease: a meta-analysis of randomized controlled trials. Qin X, Huo Y, Xie D, Hou F, Xu X, Wang X. Clin Nutr; 2013 Oct 13; 32(5):722-7. PubMed ID: 23313356 [Abstract] [Full Text] [Related]
6. Interventions for lowering plasma homocysteine levels in kidney transplant recipients. Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ. Cochrane Database Syst Rev; 2015 May 04; 2015(5):CD007910. PubMed ID: 25938479 [Abstract] [Full Text] [Related]
7. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF. Cochrane Database Syst Rev; 2014 May 31; (5):CD007784. PubMed ID: 24880031 [Abstract] [Full Text] [Related]
8. Homocysteine-lowering interventions for preventing cardiovascular events. Martí-Carvajal AJ, Solà I, Lathyris D. Cochrane Database Syst Rev; 2015 Jan 15; 1():CD006612. PubMed ID: 25590290 [Abstract] [Full Text] [Related]
9. Homocysteine-lowering interventions for preventing cardiovascular events. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Cochrane Database Syst Rev; 2013 Jan 31; (1):CD006612. PubMed ID: 23440809 [Abstract] [Full Text] [Related]
10. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M. Circulation; 2011 Apr 26; 123(16):1763-70. PubMed ID: 21482964 [Abstract] [Full Text] [Related]
15. Folic Acid Supplementation and the Risk of Cardiovascular Diseases: A Meta-Analysis of Randomized Controlled Trials. Li Y, Huang T, Zheng Y, Muka T, Troup J, Hu FB. J Am Heart Assoc; 2016 Aug 15; 5(8):. PubMed ID: 27528407 [Abstract] [Full Text] [Related]
17. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Heinz J, Kropf S, Luley C, Dierkes J. Am J Kidney Dis; 2009 Sep 15; 54(3):478-89. PubMed ID: 19359080 [Abstract] [Full Text] [Related]
18. Homocysteine lowering with folic acid and B vitamins in vascular disease. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, McQueen MJ, Probstfield J, Fodor G, Held C, Genest J, Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. N Engl J Med; 2006 Apr 13; 354(15):1567-77. PubMed ID: 16531613 [Abstract] [Full Text] [Related]